Indaptus Therapeutics

Health Canada Approves Expansion of Decoy20 Cancer Immunotherapy Trial

4 months ago

• Indaptus Therapeutics receives Clinical Trial Authorization from Health Canada to expand its ongoing U.S. clinical trial INDP-D101 for its lead cancer immunotherapy candidate Decoy20. • The company plans to submit an amendment for a combination trial pairing Decoy20 with Beigene's PD-1 checkpoint inhibitor tislelizumab, broadening the therapeutic approach. • Decoy20's unique mechanism activates both innate and adaptive immune responses through multiple pathways, showing promise in pre-clinical studies against various solid tumors.

Incyte and Indaptus Announce Key Milestones and Strategic Goals for 2025

4 months ago

• Incyte anticipates a transformational 2025 with multiple potential drug launches and pivotal trial readouts across its oncology and inflammation & autoimmunity portfolio. • Indaptus Therapeutics plans to launch a combination cohort trial of Decoy20 with BeiGene's tislelizumab and expand clinical trial sites in the first half of 2025. • Indaptus' Decoy20 demonstrated a broad immune response across multiple tumor types, showing potential as a monotherapy and in combination with checkpoint inhibitors.

Indaptus Therapeutics Advances Decoy20 Clinical Trial and Enters Supply Agreement with BeiGene

6 months ago

• Indaptus Therapeutics reported a 26% decrease in operating expenses for Q3 2024, driven by the completion of certain manufacturing processes for Decoy20. • The Phase 1 clinical trial for Decoy20 has progressed, with six patients completing one month of treatment at the 3 x 10^7 dose, and unrestricted enrollment authorized. • A clinical supply agreement with BeiGene Switzerland GmbH will advance the evaluation of Decoy20 in combination with tislelizumab, set to begin in 2025. • Indaptus is seeking additional capital to fund operations beyond Q1 2025, while facing financial and operational risks that could impact its long-term stability.

Indaptus Therapeutics and BeiGene Collaborate on Novel Cancer Immunotherapy Combination

7 months ago

• Indaptus Therapeutics and BeiGene have entered a clinical supply agreement to evaluate the combination of Decoy20 and tislelizumab in cancer treatment. • The planned clinical trial will assess the synergistic effects of Decoy20, an immune stimulator, with tislelizumab, BeiGene's anti-PD-1 antibody. • Preclinical studies have shown that Decoy20, combined with a PD-1 inhibitor, induced complete cancer regressions and immunological memory in animal models. • The clinical trial, anticipated to begin in 2025, aims to improve outcomes for challenging cancers like liver, colon, and pancreatic cancer.